Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CICC Raises 3SBIO (01530.HK) TP by 56.3%, Keeps Rating at Outperform
Recommend 7 Positive 20 Negative 3 |
||||
|
||||
|
3SBIO (01530.HK) will grant Pfizer exclusive rights for the development, production and commercialization of its PD-1/VEGF bispecific antibody (SSGJ-707) outside China, CICC published a research report saying. Pfizer will have the option for commercialization in the Chinese market. Therefore, the broker maintained its 2025/ 2026 adjusted earnings forecasts for 3SBIO at RMB2.41 billion/ RMB2.6 billion respectively, and raised its target price by 56.3% to $21.1, with rating kept at Outperform. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
